HIGHLIGHTS
- who: TYPE and colleagues from the University of Padua, Italy have published the paper: Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma, in the Journal: (JOURNAL)
- what: To confirm the possible synergism between CK2 and Bcl-2 inhibitions, the authors evaluate cell growth and calculated the CI between Frontiers in Cell and Developmental Biology frontiersin.org 10.3389/fcell.2022.935023 downstream elements, such as in the NF-κB pathway, BTK or PLCγ2 (Hershkovitz-Rokah et_al, 2018). The authors have provided strong evidence that . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.